The biotechnology company Inbiomotion, a member of Catalonia.health, has announced that its MAF Test® has been included in the SEOM-GEICAM-SOLTI 2025 Clinical Practice Guidelines for early-stage breast cancer, a key consensus document for clinical decision-making in Spain and an international reference.
The guidelines, jointly developed by the Spanish Society of Medical Oncology (SEOM), the Spanish Breast Cancer Research Group (GEICAM) and the Spanish Collaborative Group for the Study, Treatment and Other Experimental Strategies in Solid Tumours (SOLTI), recognise the MAF Test® as a tool to support clinical decision-making in patients with early-stage breast cancer.
The inclusion of the test is based on multiple clinical analyses demonstrating that the status of the MAF gene is associated with differential responses to adjuvant bisphosphonate treatment. The data show that patients with MAF-negative tumours experience improvements in invasive disease-free survival, disease-free survival and overall survival when they receive this treatment, whereas MAF-positive tumours may be associated with a higher risk of extra-skeletal recurrence.
In this context, the MAF Test® enables the refinement of patient selection for adjuvant bisphosphonates, contributing to more precise treatment personalisation and the reduction of potentially unnecessary therapies. Currently, bisphosphonates are mainly used in postmenopausal women or those undergoing ovarian suppression who are at higher risk of recurrence, but the historical lack of predictive tools had limited their individualised application.
Joël Jean-Mairet, Chief Executive Officer of Inbiomotion, commented: ‘Inclusion in the guidelines is a turning point for diagnostic innovation. It reflects the consensus of independent experts on the clinical relevance of the MAF gene in early-stage breast cancer and supports a clear objective: to help clinicians optimise decisions on adjuvant treatment, while reducing unnecessary therapy.’
Roger Gomis, Chief Scientific Officer at Inbiomotion, states: "The inclusion of the MAF® Test in the SEOM-GEICAM-SOLTI guidelines for early-stage breast cancer reflects the growing integration of tumour biology into decision-making on adjuvant treatment. It provides clinicians with an additional evidence-based option to personalise treatment and better identify patients for whom treatment may not be beneficial."
Comments